Kisqali 200mg is indicated in combination with letrozole which an aromatase inhibitor for the treatment for women with breast cancer.
Kisqali 200mg belongs to selective cyclin-dependent kinase inhibitor, a class of drugs which help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can allow cancer cells to develop and divide too fastly. Aiming CDK4/6 with improve precision may play a role in providing that cancer cells do not continue to multiply uncontrollably.
Mechanism of action
Ribociclib is a type of drug which can be needed along with an aromatase inhibitor to cure women with advanced hormone receptor-positive breast cancer. Ribociclib belongs to small molecule cyclin-dependent kinase (CDK) inhibitor. The drug stops proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, inhibiting these proteins helps to block the cells from segregate to make new cells. It helps inhibit the cells from moving from G1 to S cell cycle phase in the division process. This reduce cancer growth. The Co administration of Ribociclib and an aromatase inhibitor (e.g. letrozole) is more active compared with each agent alone.
The prescribed dose of Kisqali is 600mg (three 200mg film coated tablets) administrated orally once daily for 21 consecutive days followed by 7 days off therapy resulting in a complete cycle of 28 days The drug Kisqali can be administrated with or without food. Overdose: overdose with Kisqali in human has experienced very limited. In case occurs provide general symptomatic and supportive measures.
• Decreased in blood counts
• Nausea and vomiting
• Increased liver enzymes
• Hair loss
• Decreased kidney function
• Lack of appetite
• Urinary tract infection.
Kisqali has been exposed to prolong the QT interval in a concentration-dependent manner. Based on the observed QT prolongation during therapy, Kisqali may needed dose interruption, reduction, or discontinuation. Avoid the combination use with tamoxifen due to increased QT prolongation. In patients with advanced or metastatic breast cancer will increases in transaminases were resulted; perform liver function test before starting treatment with Kisqali; based on severity of the transaminase elevations, Kisqali may require dose interference, reduction or stopping.